The Michael J. Fox Foundation for Parkinson’s Research (MJFF) recognized a Texas scientist for his contributions to Parkinson’s research and his commitment to mentoring the next generation of Parkinson’s scientists. Claudio Soto, PhD, a professor of neurology and director of the George and Cynthia Mitchell Center for Alzheimer’s…

PreciseDx’s artificial intelligence (AI) platform shows an ability to accurately diagnose Parkinson’s disease in people before they develop severely evident symptoms, according to a new study. Conducted in collaboration with The Michael J. Fox Foundation (MJFF), the study’s findings support the platform’s potential to aid in diagnosing Parkinson’s and allowing patients to begin…

A positron emission tomography (PET) tracer for the alpha-synuclein protein, whose damaging clumps mark Parkinson’s, captured its toxic aggregates in a living brain for a first time — instead of in post-mortem tissue as is done to date, scientists reported. The tracer, called ACI-12589, is a diagnostic tool designed to…

Scientists from Northwestern University will use two grants — totaling $17.9 million — from the Aligning Science Across Parkinson’s (ASAP) initiative to study alterations in the brain that contribute to the development of Parkinson’s disease. Their research focuses on brain circuits, the specific populations of interconnected brain cells…

The Parkinson’s Progression Markers Initiative (PPMI), a study sponsored by The Michael J. Fox Foundation, is recruiting people with known disease risk factors but no official Parkinson’s diagnosis, the foundation announced. Newly diagnosed patients, and healthy adults — those without any known Parkinson’s risk factors, who would…

People with Parkinson’s disease experience more stress than those without this disease, and high stress levels associate with a worsening of symptoms, research based on a patient survey reported. Mindfulness, a practice of maintaining a heightened state of awareness of thoughts and feelings, may help to lower stress…

Researchers have developed a faster method of measuring the rate at which alpha-synuclein protein forms toxic clumps that reliably distinguishes people with Parkinson’s disease from those without the condition. The findings support the use of this test — which cuts by more than half the time required to obtain…

Participants are now being recruited for several clinical trials testing investigational treatments for Parkinson’s disease, The Michael J. Fox Foundation (MJFF) announced. Clinical trials are well-designed experiments conducted on human participants. Since such trials actually test a treatment in people, these studies are essential for understanding whether a given…

Two nonprofits, Parkinson’s U.K. and The Michael J. Fox Foundation have partnered with Neurolixis to support a clinical trial testing the safety, tolerability, and early efficacy of NLX-112, the company’s candidate to ease  dyskinesia and the severity of some non-motor symptoms due to Parkinson’s disease. Data from…

The Parkinson’s Progression Markers Initiative (PPMI), a study sponsored by The Michael J. Fox Foundation, is expanding to recruit more participants, the Foundation announced. Currently, the study (NCT04477785) is recruiting new participants — both with and without Parkinson’s disease — at Banner Research Institute in…